@article {7691,
	title = {Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma},
	journal = {Leukemia},
	volume = {25},
	year = {2011},
	note = {Cited By :13Export Date: 21 February 2017},
	month = {2011},
	pages = {1620 - 1626},
	abstract = {This analysis assessed the effect of lenalidomide on progression-free survival (PFS). Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenalidomide at 12 months were included. The median follow-up of surviving patients was 48 months. Of 353 patients who received lenalidomide plus dexamethasone, 116 (33\%) had not progressed. Overall, 52 patients (45\%) had no dose reductions, 25 (22\%) had dose reductions >=12 months and 39 (34\%) had dose reductions before 12 months. Patients who had dose reductions >=12 months had a significantly longer median PFS than those who had reductions before 12 months (P=0.007) or no dose reductions (P=0.039) (not reached vs 28.0 vs 36.8 months, respectively). In a multivariate Cox regression model, dose reduction >=12 months was an independent predictor of improved PFS (hazard ratio, 0.47; 95\% confidence interval, 0.23-0.98) after adjusting for patient characteristics. The data suggest that to achieve maximum PFS benefit, patients with RRMM should be treated for >=12 months with full-dose lenalidomide plus dexamethasone. Thereafter, patients may benefit from lower-dose continued therapy; prospective studies are needed to confirm these findings. {\textcopyright} 2011 Macmillan Publishers Limited All rights reserved.},
	keywords = {Dexamethasone, Lenalidomide, multiple myeloma, progression-free survival, refractory, relapsed},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-80054028441\&doi=10.1038\%2fleu.2011.126\&partnerID=40\&md5=2abcb129829b982e606a69d5b8fc443f},
	author = {Dimopoulos, M.A. and Hussein, M. and Swern, A.S. and Weber, D.}
}
